Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLN124 in NTD Beta-thalassemia and Low Risk MDS
NCT04176653Phase 1Withdrawn
- Sponsor
- Silence Therapeutics
- Start
- Aug 2019
- Primary completion
- Sep 2021
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of SLN124 in beta thalassemia and myelodysplastic syndrome (MDS) (5 arms), sponsored by Silence Therapeutics. Primary endpoints: Number of participants with all adverse events up to 2 months, 12 lead electrocardiogram parameters up to 2 months and 2 more. Planned start Aug 2019; status: withdrawn.
02
Drugs
SLN124
03
Conditions
beta thalassemiamyelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04176653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04176653.